Viral infections:

Indications for: COMBIVIR

HIV-1 infection, in combination with other antiretroviral agents.

Adults and Children:

<30kg: not recommended. ≥30kg: 1 tab twice daily. Hepatic or renal impairment (CrCl <50mL/min): not recommended; use individual components.

Boxed Warning:

Hematologic toxicity. Myopathy. Lactic acidosis and severe hepatomegaly with steatosis. Exacerbations of hepatitis B.

COMBIVIR Warnings/Precautions:

Risk of hematologic toxicity/bone marrow suppression; monitor CBCs esp. in advanced HIV-1 disease; interrupt dose if anemia or neutropenia occurs. Myopathy with prolonged zidovudine use. Suspend if lactic acidosis or pronounced hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Not for treating chronic HBV infection; closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted. History of pancreatitis. Monitor for lipoatrophy; use alternatives if suspected. Women. Obesity. Elderly. Pregnancy. Nursing mothers: not recommended.

COMBIVIR Classification:

Nucleoside analogues (reverse transcriptase inhibitors).

COMBIVIR Interactions:

Avoid concomitant stavudine, doxorubicin, nucleoside analogues (eg, ribavirin), sorbitol-containing products. Increased hematologic toxicity with ganciclovir, interferon alpha, ribavirin, other bone marrow suppressants or cytotoxic drugs. Monitor for treatment-associated toxicities (eg, hepatic decompensation) with interferon-alpha with or without ribavirin.

Adverse Reactions:

Headache, nausea, malaise, fatigue, nasal symptoms, diarrhea, cough; neutropenia, anemia, lactic acidosis, severe hepatomegaly with steatosis, myopathy, myositis, immune reconstitution syndrome, pancreatitis (discontinue if occurs), lipoatrophy.

Note:

Register pregnant patients exposed to lamivudine by calling (800) 258-4263.

How Supplied:

Tabs—60